Legislative Initiatives and Review of Abuse-Deterrent Opioid Formulations

被引:0
|
作者
Ng, Kimberly Erin [1 ]
Ahmed, Ebtesam [1 ]
Saad, Maha [1 ]
机构
[1] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Opioid analgesics are the mainstay treatment of moderate-to-severe pain. However, opioids carry a risk of misuse, abuse, and death, and recently have become a public health challenge. In response to the steady increase in opioid abuse, pressure has been growing on pharmaceutical companies to develop prescription opioid formulations that help deter abuse while remaining readily accessible for pain management. This article discusses some of the novel abuse-deterrent formulation methods, including aversion, physical barrier, and agonist-antagonist. It also addresses some of the legislative initiatives and the role of pharmacists in providing education to health care professionals and patients as well as increasing their awareness of prescription opioid misuse and abuse.
引用
收藏
页码:21 / 26
页数:6
相关论文
共 50 条
  • [41] A New Abuse-Deterrent Opioid - Xtampza ER
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1497): : 77 - 78
  • [42] PREVENTING PROVIDER MISINFORMATION AND IMPROVING OVERSIGHT OF ABUSE-DETERRENT OPIOID FORMULATIONS: A POLICY ANALYSIS
    Adams, Elizabeth T.
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2020, 54 : S57 - S57
  • [44] Beta-glucan and arabinogalactan-based xerogels for abuse-deterrent opioid formulations
    Veverka, Miroslav
    Dubaj, Tibor
    Veverkova, Eva
    Simon, Peter
    Husar, Stefan
    Tomanova, Katarina
    Jorik, Vladimir
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 129 : 132 - 139
  • [45] Characterizing patients using abuse-deterrent formulations of extended-release opioid analgesics
    Oh, Gyeon
    DiPrete, Bethany
    Slavova, Svetla
    Dasgupta, Nabarun
    Ranapurwala, Shabbar I.
    Slade, Emily
    Delcher, Chris
    Moga, Daniela C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 165 - 166
  • [46] Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?
    Kaddis, Atheer A.
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2020, 13 (01): : 30 - 31
  • [47] Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States Lessons Learned From OxyContin
    Cicero, Theodore J.
    Ellis, Matthew S.
    [J]. JAMA PSYCHIATRY, 2015, 72 (05) : 424 - 429
  • [48] ABUSE-DETERRENT FORMULATIONS OF OPIOIDS: EFFECTIVENESS AND ECONOMIC IMPACT
    Siddiqi, S. A.
    Islam, M. Z.
    Siddiqi, K. A.
    Haider, M. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S191 - S191
  • [49] A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process
    Bhola, Jaydip
    Borkhataria, Chetan
    [J]. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2024,
  • [50] ABUSE-DETERRENT FORMULATIONS OF OPIOIDS: EFFECTIVENESS AND ECONOMIC IMPACT
    Agboola, F. O.
    Kumar, V. M.
    Synnott, P. G.
    Chapman, R. H.
    Banken, R.
    Ollendorf, D. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S191 - S191